Knowledge about the biology of diffuse large B-cell lymphoma (DLBCL) and the number of treatments approved for the disease continues to grow.
This three-question quiz will test one aspect from each article in 鶹ý's Clinical Challenges series on DLBCL that covered the following: use of bispecific antibodies versus CAR T-cell therapy in the relapsed/refractory disease setting; adoption of the first-line regimen of polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP); and the prophylaxis and treatment of central nervous system (CNS) relapse.
Correct answers and explanations appear after completing the quiz.